These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1150 related items for PubMed ID: 12814430

  • 1. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.
    Vermeulen K, Van Bockstaele DR, Berneman ZN.
    Cell Prolif; 2003 Jun; 36(3):131-49. PubMed ID: 12814430
    [Abstract] [Full Text] [Related]

  • 2. Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
    Senderowicz AM.
    Cancer Biol Ther; 2003 Jun; 2(4 Suppl 1):S84-95. PubMed ID: 14508085
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L, Siu KT, Raje N.
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cyclins and related kinases in cancer cells.
    Malumbres M.
    J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Small-molecule cyclin-dependent kinase modulators.
    Senderowicz AM.
    Oncogene; 2003 Sep 29; 22(42):6609-20. PubMed ID: 14528286
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
    Grant S, Roberts JD.
    Drug Resist Updat; 2003 Feb 29; 6(1):15-26. PubMed ID: 12654284
    [Abstract] [Full Text] [Related]

  • 11. Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
    Santamaria D, Ortega S.
    Front Biosci; 2006 Jan 01; 11():1164-88. PubMed ID: 16146805
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cyclin-dependent kinase inhibitors: novel anticancer agents.
    Mani S, Wang C, Wu K, Francis R, Pestell R.
    Expert Opin Investig Drugs; 2000 Aug 01; 9(8):1849-70. PubMed ID: 11060782
    [Abstract] [Full Text] [Related]

  • 16. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
    Senderowicz AM.
    Hematol Oncol Clin North Am; 2002 Oct 01; 16(5):1229-53. PubMed ID: 12512390
    [Abstract] [Full Text] [Related]

  • 17. The history and future of targeting cyclin-dependent kinases in cancer therapy.
    Asghar U, Witkiewicz AK, Turner NC, Knudsen ES.
    Nat Rev Drug Discov; 2015 Feb 01; 14(2):130-46. PubMed ID: 25633797
    [Abstract] [Full Text] [Related]

  • 18. Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development-Review.
    Łukasik P, Załuski M, Gutowska I.
    Int J Mol Sci; 2021 Mar 13; 22(6):. PubMed ID: 33805800
    [Abstract] [Full Text] [Related]

  • 19. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
    Fischer PM.
    Curr Opin Drug Discov Devel; 2001 Sep 13; 4(5):623-34. PubMed ID: 12825457
    [Abstract] [Full Text] [Related]

  • 20. Revisiting the "Cdk-centric" view of the mammalian cell cycle.
    Malumbres M.
    Cell Cycle; 2005 Feb 13; 4(2):206-10. PubMed ID: 15655365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.